Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy

Chuanhui Han,Anli Zhang,Zhida Liu,Casey Moore,Yang-Xin Fu

DOI: https://doi.org/10.1038/s41388-020-01575-7

IF: 8.756

2020-12-07

Oncogene

Abstract:Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an increasingly appealing therapeutic strategy for cancer patients. However, only a small portion of patients responds to anti-PD treatment. Therefore, treatment strategies are urgently needed to reverse the ICB-resistant tumor microenvironment (TME). It has become clear that the TME has diminished innate sensing that is critical to activate adaptive immunity. In addition, tumor cells upregulate various immunosuppressive factors to diminish the immune response and resist immunotherapy. In this review, we briefly update the current small molecular drugs that could synergize with immunotherapy, especially anti-PD therapy. We will discuss the modes of action by those drugs including inducing innate sensing and limiting immunosuppressive factors in the TME.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The main issue this paper attempts to address is how to remodel the tumor microenvironment (TME) with small molecule drugs to enhance the efficacy of immunotherapy, particularly in synergy with anti-programmed death receptor 1 (anti-PD-1) and anti-programmed death ligand 1 (anti-PD-L1) therapies. The paper points out that although immune checkpoint blockade (ICB) therapies have made significant progress in cancer treatment, only a small number of patients respond to this treatment. Therefore, there is an urgent need to develop new therapeutic strategies to reverse the ICB-resistant tumor microenvironment. The paper explores the current small molecule drugs available for synergistic use with immunotherapy, including mechanisms that induce innate sensing and limit immunosuppressive factors in the tumor microenvironment.

Specifically, the paper discusses the following aspects:
1. **Triggering innate sensing**: Enhancing anti-tumor immune responses by activating pattern recognition receptors such as Toll-like receptors (TLRs) and the cGAS-STING pathway.
2. **Inhibition of immunosuppressive signals**: Reducing immunosuppression in the tumor microenvironment by targeting immunosuppressive factors such as TAM receptors, thereby awakening anti-tumor immunity.
3. **Immunological effects of conventional anti-cancer therapies**: Exploring how some conventional small molecule anti-cancer drugs (such as EGFR tyrosine kinase inhibitors, PARP inhibitors, etc.) can enhance the efficacy of immunotherapy by inducing immunogenic cell death (ICD) or directly activating innate sensing pathways.

The paper emphasizes that combining small molecule drugs with immunotherapy can significantly improve anti-tumor effects, extend patient survival, and proposes some specific clinical trial results and future research directions.